Vaxcyte heads into earnings miss with shorts building and peers outrunning it
PCVX reported Q1 2026 results after the close on May 6 — an EPS of -$2.30 against a -$1.82 consensus estimate — capping a week in which the stock already slid 5.3% to $55.64 and short interest climbed to its highest…